Case Details
- Citation: [2016] SGHC 275
- Title: Goh Seng Heng v RSP Investments and others and another matter
- Court: High Court of the Republic of Singapore
- Date of Decision: 12 December 2016
- Judge: Lai Siu Chiu SJ
- Coram: Lai Siu Chiu SJ
- Case Numbers: Suit No 546 of 2015 (Summons No 1124 of 2016) and Suit No 111 of 2016 (Summonses Nos 554, 754 and 934 of 2016)
- Procedural Posture: Applications for injunctions and related relief; appeals pending/considered alongside related interlocutory decisions (with Court of Appeal later addressing appeals in 2017)
- Plaintiff/Applicant: Dr Goh Seng Heng
- Defendants/Respondents: RSP Investments and others; and in the related suit, Dr Goh, Michelle Goh and Quikglow Pte Ltd
- Legal Areas: Civil Procedure — Injunctions; Civil Procedure — Mareva injunctions
- Key Applications Mentioned: (i) Dr Goh’s application for an injunction to restrain defendants from calling meetings to alter share capital (Summons No 1124 of 2016); (ii) AM group’s Mareva application to restrain disposal of assets (Summons No 754 of 2016); (iii) AM group’s application for an injunction restraining competitive conduct (Summons No 554 of 2016); (iv) setting aside application against Mareva and other injunction (Summons No 934 of 2016); (v) joinder application (Summons No 755 of 2016)
- Parties (Principal): Dr Goh Seng Heng; Aesthetic Medical Partners Pte Ltd (Company); Aesthetic Medical Holdings Pte Ltd (AMH); RSP Investments (RSP); Terence Loh and Nelson Loh; Motcombe Holdings Limited; Justin Demetrio Reis and Peter Anthony Reis; Quikglow Pte Ltd; PPP Investments Pte Ltd; Lee Kin Yun; Koh Mui Lee; Melissa Goh
- Judicial Note / Editorial Note: Appeals in Civil Appeal No 114 of 2016 (plaintiff in Suit 546/2015) and Civil Appeals Nos 115 and 116 of 2016 (defendants in Suit 111/2016) were heard by the Court of Appeal on 13 April 2017. CA 114/2016 dismissed; CA 115/2016 allowed; orders made for CA 116/2016 with no written grounds rendered.
- Counsel (Summary): For Dr Goh in Suit 546/2015 and first to third defendants in Suit 111/2016: Goh Chee Hsien, Joel Lim Siok Khoon, Ong Pei Ching, Tan Gim Hai Adrian and Yeoh Jean Wern (Morgan Lewis Stamford LLC). For first to third defendants in Suit 546/2015: Suresh S/O Damodara (Damodara Hazra LLP). For fourth to sixth defendants in Suit 546/2015: Pereira Kenetth Jerald, Sujatha Selvakumar and Wee Jia Min (Aldgate Chambers LLC). For first and second plaintiffs in Suit 111/2016: N Sreenivasan SC and others (Straits Law Practice LLC).
Summary
This High Court decision arose from a shareholder and investor dispute within a Singapore company operating aesthetic laser clinics and skincare-related services. The litigation was not merely a commercial disagreement; it was framed as a “power struggle” involving competing claims to control corporate decision-making, including the ability to call meetings and alter share capital, as well as allegations of fiduciary and contractual breaches and conspiracy. The court dealt with multiple interlocutory applications across two suits, including applications for injunctions and a Mareva injunction to restrain dissipation of assets.
At the core of the decision was the court’s assessment of whether the applicants had established the requisite threshold for interim relief—particularly where the relief sought could affect corporate governance and where the Mareva order would restrain the defendants’ dealings with assets. The judge applied established principles for injunctions and Mareva relief, focusing on the existence of a serious question to be tried, the adequacy of damages, and the balance of convenience. In relation to the Mareva injunction, the court also considered the risk of asset dissipation and the evidential basis for concluding that such risk existed.
What Were the Facts of This Case?
The Company, Aesthetic Medical Partners Pte Ltd, was incorporated in August 2008 and operates outlets in Singapore providing aesthetic laser services and skincare-related products. Dr Goh Seng Heng, a dermatologist by training, was the managing director and remained a shareholder. His daughters, Dr Michelle Goh and Melissa Goh, were directors, and Michelle remained a shareholder. Together with Dr Goh’s company, Dr Goh Seng Heng Pte Ltd, Dr Goh and Michelle held 13.31% of the Company’s shares.
By late 2013 and into 2014, the dispute developed around the involvement of investors and the structuring of shareholdings. A fund called Lion Rock Capital (“Lion Rock”) wanted to invest in the Company. Nelson Loh, acting as a director of RSP Investments, was tasked with structuring a deal between the Company and Lion Rock. Dr Goh alleged that Nelson, without board approval, sought to arrange for Lion Rock to buy shares held by Nelson and Justin, which led to disagreements between Dr Goh, RSP, and Justin.
On 24 January 2014, the parties reached a settlement agreement (“the Settlement Agreement”). Under that agreement, Motcombe Holdings Limited transferred 18,696 shares out of its 62,319 shares to RSP. RSP already held 50,000 shares. Further, RSP, Terence Loh, and Nelson Loh agreed to appoint Dr Goh or Michelle as their proxies or representatives at general meetings and to sign resolutions on their behalf. Justin and Peter Anthony Reis (Justin’s father) similarly agreed to appoint Dr Goh and Michelle as proxies and representatives for general meetings. The Settlement Agreement also provided for Motcombe to transfer its remaining shares (after the initial transfer to RSP) to a “Motcombe transferee” acceptable to Dr Goh; Peter became that transferee in February 2014.
In late 2014, Dr Goh purchased additional shares from Peter, leaving Peter with 24,994 shares. Dr Goh also entered into further arrangements, including an agreement dated 17 September 2014 to purchase shares from RSP in the event of an IPO or trade sale. Importantly, Dr Goh and Michelle sought to secure voting control through proxy arrangements with other shareholders, including Lucy. Dr Goh alleged that despite these agreements, the defendants refused to provide executed proxy forms for an extraordinary general meeting scheduled for 9 June 2015 (“the June EGM”), prompting him to seek interim relief to preserve the status quo.
What Were the Key Legal Issues?
The first major issue concerned whether Dr Goh should obtain an injunction restraining RSP and the other defendants from calling meetings for the purpose of altering the Company’s share capital, including allotting and/or issuing shares and voting to alter share capital. This raised questions about the court’s willingness to grant interim relief that directly affects corporate governance and shareholder decision-making, and whether Dr Goh had demonstrated a sufficient basis for the court to intervene before trial.
The second major issue concerned the AM group’s Mareva injunction. The AM group (the Company and its wholly owned subsidiary AMH) obtained a Mareva order restraining Dr Goh and requiring disclosure of assets in Singapore. The legal questions included whether the plaintiffs had established a serious case on the merits (including claims for breach of fiduciary and/or contractual duties and conspiracy), and whether there was a real risk that the defendants would dissipate assets such that any judgment would be rendered ineffectual. The court also had to consider whether the scope of the Mareva relief was proportionate and justified on the evidence.
Finally, the court had to address related injunction issues, including an injunction restraining Dr Goh and Michelle from joining Quikglow and engaging in the same or similar business as the AM group, and the defendants’ application to set aside the Mareva and other injunctions. These issues required the court to apply the same interim relief framework while balancing competing interests, including the effect on ongoing business operations and the defendants’ ability to conduct their affairs.
How Did the Court Analyse the Issues?
The judge began by situating the dispute within the context of interim relief. The court emphasised that injunctions are equitable remedies granted to preserve rights pending trial, but they are not granted automatically. The applicant must show, at minimum, that there is a serious question to be tried. Where the injunction sought is negative in substance—restraining certain conduct—the court still assesses whether the applicant’s case is sufficiently strong and whether the balance of convenience favours the grant of interim restraint.
For Dr Goh’s application to restrain the defendants from calling meetings to alter share capital, the court considered the practical consequences of granting such relief. Interim orders that prevent shareholders from convening meetings or voting on corporate actions can have significant effects on corporate governance and may interfere with legitimate corporate processes. Accordingly, the court examined whether Dr Goh’s allegations about refusal to provide executed proxy forms and the risk of being removed from board control were supported by evidence sufficient to justify the extraordinary step of restraining the defendants’ ability to convene meetings.
In relation to the Mareva injunction, the court applied the established Mareva framework. The judge considered whether the plaintiffs had demonstrated a serious case on the merits, which in this case involved allegations that Dr Goh and Michelle breached fiduciary and/or contractual duties and engaged in conspiracy by lawful and/or unlawful means, including through the establishment and competitive operation of Quikglow. The court also considered the nature of the relief sought: a Mareva injunction is designed to prevent a defendant from frustrating the enforcement of a future judgment by dissipating assets. Therefore, the court focused on whether there was evidence of a risk of dissipation or other conduct that would make enforcement difficult.
The court also addressed the evidential basis for the Mareva order, including the need for disclosure and the proportionality of the restraint. The Mareva order in this case restrained Dr Goh from disposing of assets up to the value of $10m and required disclosure of assets in Singapore. The judge’s analysis reflected the principle that Mareva relief is exceptional and must be justified by concrete evidence rather than speculation. Where the evidence indicates that the defendant’s conduct or circumstances create a genuine risk of dissipation, the court may grant interim restraint; where the evidence is insufficient, the court should be cautious.
On the setting aside application, the court considered whether the defendants had shown that the Mareva injunction and other injunctions should not have been granted. Setting aside an interim order requires more than disagreement with the outcome; the applicant must typically demonstrate that the order should not stand because the legal or factual basis for it is not sound. The judge therefore revisited the interim relief criteria and the evidence relied upon at the time the orders were granted, including whether the plaintiffs had met the threshold for the grant and whether the scope of the orders was appropriate.
What Was the Outcome?
The High Court dismissed Dr Goh’s application for an injunction restraining the defendants from calling meetings to alter share capital. The court’s decision meant that, pending trial, the defendants were not restrained from convening meetings for the relevant purposes. This preserved the defendants’ ability to pursue corporate actions through meetings, subject to the eventual determination of the substantive claims.
In the related proceedings, the court also dismissed the setting aside application brought by Dr Goh, Michelle and Quikglow against the Mareva injunction and the injunction granted in favour of the AM group. Practically, this meant that the Mareva restraint and the competitive injunction remained in force at least through the interlocutory stage, continuing to limit the defendants’ ability to dispose of assets and to engage in the restrained competitive conduct.
Why Does This Case Matter?
This case is significant for practitioners because it illustrates how Singapore courts approach interim relief in complex corporate disputes where the relief sought can materially affect governance and enforcement. The decision underscores that injunctions—particularly those that interfere with corporate decision-making—require careful scrutiny of evidence and the balance of convenience. Even where a shareholder alleges wrongdoing and seeks to preserve a status quo, the court will not grant restraint unless the applicant demonstrates a sufficiently strong case and a compelling need for interim intervention.
For Mareva injunctions, the case highlights the court’s insistence on an evidential foundation for risk of dissipation and on proportionality. Mareva relief is designed to protect the efficacy of a future judgment, but it is not a substitute for proof of the underlying claims. Practitioners should take from this decision the importance of presenting concrete evidence supporting the risk of dissipation and ensuring that the scope of the restraint is tailored to what is justified.
Finally, the decision is useful for understanding how courts handle multi-suit, multi-application litigation where injunctions, joinder, and setting aside motions arise in parallel. The case demonstrates that interim relief is often granted and contested in a dynamic procedural environment, and that courts will apply consistent legal principles while remaining attentive to the practical impact of orders on corporate operations and parties’ conduct.
Legislation Referenced
- Companies Act (Singapore) — provisions relating to fraudulent trading and related corporate liability concepts (as referenced in the judgment’s discussion of claims against parties)
Cases Cited
- [2016] SGHC 275 (the present decision)
Source Documents
This article analyses [2016] SGHC 275 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.